Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Trialsmashartificial-intelligenceclinical-trials

Hepatology Review Maps AI Applications for MASH Clinical Trials

Authors outline how artificial intelligence could improve patient selection, histology reading and endpoints in MASH drug development.

PR
By Priya Raman · Science Reporter
Sep 15 20:00 ETSource: Hepatology international

The wire

  1. 01Hepatology International publishes guidance on applying AI to facilitate MASH trials.
  2. 02MASH trials are costly and biopsy-dependent, a bottleneck for metabolic drug developers.
  3. 03Adoption by sponsors and regulators remains untested.

From the source

How to apply artificial intelligence (AI) to facilitate and enhance MASH trials

Hepatology international · 2026 Sep 16 · Lim DYZ, Leow WQ, Allende DS et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42749968/